Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing a regenerative cartilage repair technology called GelrinC, which was recently highlighted for its potential to address a significant unmet need in orthopedic medicine. The company's lead product is a cell-free, off-the-shelf degradable hydrogel implant designed to support the regeneration of knee cartilage. According to the company, GelrinC gradually resorbs over approximately six to nine months as new tissue fills the treated area.
The technology aims to provide durable, long-term treatment outcomes, a growing focus in orthopedic medicine. Regentis reports that its Pilot/Phase II study showed 100% greater pain improvement compared with traditional microfracture treatment. Additionally, 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality.
GelrinC has received a CE mark in Europe, providing a pathway for commercialization in that market. Meanwhile, Regentis is advancing its pivotal Phase III clinical study in the United States and preparing for the FDA's Premarket Approval process. The company is also working to complete enrollment in its U.S. study and expand commercialization efforts.
The potential impact of this announcement is significant for patients suffering from knee cartilage damage. Regentis estimates that GelrinC addresses a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. If approved, GelrinC could offer a new option for cartilage repair, potentially reducing pain and improving mobility for patients.
For investors, Regentis Biomaterials is listed on the NYSE American under the ticker RGNT. The company's progress with GelrinC, including the Phase III trial and preparation for FDA approval, represents key milestones. More information about Regentis Biomaterials can be found through Regentis Biomaterials (NYSE American: RGNT) and the latest news and updates are available in the company's newsroom at https//ibn.fm/RGNT. To view the full article, visit https://ibn.fm/cTSlo.
The announcement was disseminated as part of a paid investor awareness and marketing engagement on behalf of Regentis Biomaterials Ltd. by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
